Testing effectiveness (Phase 2)Study completedNCT06482112
What this trial is testing
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
Who this might be right for
Metabolic Dysfunction-Associated Steatotic Liver DiseaseNon-alcoholic Fatty Liver DiseaseNonalcoholic Fatty Liver Disease+1 more
Merck Sharp & Dohme LLC 124